08
Jul

AstraZeneca and Ironwood Pharmaceuticals say their Phase III study for linaclotide, conducted primarily in China among patients with irritable bowel syndrome with constipation, came through on all primary and secondary endpoints.

…read more

Source: AstraZeneca, Ironwood score PhIII success in China

    

0 No comments